Europe’s premier life science legal strategy forum returns to Frankfurt, 12th-13th October 2027, with a continued emphasis on seniority and holistic, cross-practice discussion.

Uniting senior legal leaders from across pharma, biotech and the broader life science sector, LSLS 2027 will once again dive into practical and lived experiences of practitioners discussing the overall life science strategy sector, including IP, exclusivity, market access, transactions, competition and compliance. Get ready for nuanced debate, actionable takeaways and senior networking opportunities, which will help you sharpen your legal strategy and establish key contacts tailored to your work.

2026 Featured Speakers Include

550+
Attendees
100+
Speakers
10+
Hours of Dedicated Networking
50%
In-House Counsel

Discussion topics to look forward to at
LSLS 2027
will include 

Holistic Keynote Discussions

Learn how the industry is responding to cross-practice challenges, from loss of exclusivity and the rise of AI to the EU Pharma Package, geopolitics and Europe's place in the global life science market. Featuring insights from General Counsel, senior policymakers, private practice experts and more.

IP & Exclusivity Strategy

Receive high-level, actionable insights from Europe, the U.S., Brazil, China and beyond on the most pressing challenges shaping patent protection and exclusivity, from SPCs and combination therapies to biologics, plausibility and post-grant patent strategy across jurisdictions.

Policy & Market Access

Dive into the intersections between life science policy and practice, with dedicated sessions covering pricing & reimbursement, Health Technology Assessment (HTA), Most Favoured Nation (MFN) pricing, orphan and paediatric therapies, the EU Pharma Package and more.

Transactions

Explore how to execute transactions that withstand scrutiny and protect value, through high-level sessions on licensing, merger control, AI-driven collaborations, China and life science M&A disputes.

Competition & Compliance

Understand where enforcement risk is crystallising right now, from enforcer priorities, antitrust disputes, excessive pricing, parallel trade and exclusionary abuses to health data ecosystems, critical health infrastructure, HCP/HCO interactions, ESG and sanctions.

Our Audience

Uniting senior in-house counsel with private practice experts, associations, regulators, judicial faculty, legal service providers and more, LSLS is the definitive meeting point to sharpen your holistic life science legal strategy and gain actionable insights you can apply to your day-to-day work.

50%
In-House Counsel
35%
Law Firms & Specialist Consultants
10%
Service Providers
5%
Regulators, Authorities & Industry Bodies

Who You’ll Meet

The summit brings together the full spectrum of life science legal stakeholders, creating a uniquely multi-perspective and commercially focused forum for strategic discussion. 

Who
Who

Life Sciences

Who You’ll Meet - MOBILE VIEW ONLY

Who
Who

2026 Attendees Include



Fleur Herrenschmidt
“Broad range of topics (IP, Regulatory, Competition, General Legal, Market Access, Macroeconomic context) and good variety of format (from full plenary to small round table) given good insights and opportunities for interactive sessions.”
Fleur Herrenschmidt
Chief Legal & Compliance Officer |  Norgine
Lisa-Cathrin Uebel

“What a fantastic event! LSLS was a great mix of inspiring people, meaningful conversations and a truly positive atmosphere. I loved being part of it and am already looking forward to the next one.”

Lisa-Cathrin Uebel
Senior Legal Counsel |  STADA ARZNEIMITTEL AG
Georg Fuchs
“It is a great opportunity to stay informed about the latest legal developments, gain insights into current policy issues in our field, and network with other patent law professionals.”
Georg Fuchs
Head of HP Patent Strategies |  Boehringer Ingelheim
Lena Moran-Adams
“Great to see LSLS embracing the cross-practice divergence necessary to drive legal and IP excellence in the current world - very well done, with many roundtable opportunities to discuss key topics and learn together. I will be back, thanks!”
Lena Moran-Adams
Group General Counsel |  Gruba
David Pountey
"Excellent networking, and the sessions were very useful and superbly delivered."
David Pountey
Senior European Counsel, Legal & IP |  Glenmark Pharmaceuticals
Nicola Smith
“Incredible energy, brilliant people and relevant on-point topics.”
Nicola Smith
Head Global Legal & Compliance Bio Commercial & Transactions |  Sandoz

Our 2026 Partners

Photo Gallery

Loading